pharmaceuticals

  • Sam Patrick posted an article
    Biopharma research is an important source of jobs, tax revenue and research spending in SC see more

    New findings show biopharma research companies a source of jobs, tax revenue and research spending in state

     

    GREENVILLE, S.C., October 4, 2018 – This week, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report that finds there are more than 572 active clinical trials in the South Carolina, and the life science industry supports 29,500 high-quality jobs and contributes $7.9 billion to South Carolina’s economy. These clinical trials can be responsible for more than half of the $2.6 billion average cost of developing one new medicine. They are investigating some of the biggest health care challenges South Carolinians face, including arthritis, cancer, diabetes, cardiovascular disease, and Alzheimer’s disease.

    The report, titled “Research in Your Backyard: Developing Cures, Creating Jobs, Pharmaceutical Clinical Trials in South Carolina,” was released at a press event held at the Westin Poinsett today, which featured a panel discussion including researchers and executives from the Greenville Health System, KIYATEC, the Hollings Cancer Center at MUSC, and the Greenwood Genetic Center, moderated by SCBIO President and CEO, Sam Konduros.

    “Clinical trials offer patients novel medical treatments right here in the Palmetto State, while also allowing biopharma research organizations to innovate and grow,” said Konduros. “Across South Carolina, the life sciences and healthcare industries have had a profound impact on our economy and citizens, that continues to rapidly increase.”

    Clinical trials are a vital component of bringing new life-saving drugs and treatments to market. On average, it takes approximately a decade for new medicines to go through the rigorous Food and Drug Administration (FDA) approval process. Only 12 percent of drugs successfully make it through clinical trials. Since 2004, biopharmaceutical research companies have conducted or are currently conducting more than 4,700 clinical trials in South Carolina. In 2013 alone, the nearly 1,100 active clinical trials in the state generated an estimated economic impact of $540 million.

    “One of the most important things we want people to understand about medicine development is that clinical trials rely on patient participation,” said Nick McGee, Director of Public Affairs for PhRMA. “It’s incredibly important that patients are aware of ongoing trials and learn how they can help become part of finding a cure for the toughest chronic conditions and diseases we face today.”

    In the United States, there are more than 7,000 open clinical trials being sponsored by the biopharmaceutical industry, universities, individuals and organizations combined. In South Carolina, of the 572 open clinical trials involving the biopharmaceutical research industry, the University of South Carolina Medial School is collaborating on more than 143 clinical trials and the Medical University of South Carolina is collaborating on more than 142.

    “Many top research and medical universities call South Carolina home and are centers of innovation,” Bob Quinn, Executive Director of the South Carolina Research Authority, said. “Maintaining strong partnerships between our universities and life science companies allows us to foster developments right here in South Carolina that can then help save lives far beyond our state lines.”

    You can read the complete report, “Research in Your Backyard: Developing Cures, Creating Jobs, Pharmaceutical Clinical Trials in South Carolina,” here.

    ###

    About PhRMA
    The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $71.4 billion in 2017 alone.

    About SC BIO
    SCBIO is South Carolina’s investor-driven public/private economic development organization focused on building, advancing, and growing the life sciences industry in the state.  With an $11.4 billion annual economic impact in the Palmetto State, with more than 400 firms and 15,000 professionals directly involved in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products that make a difference across the Palmetto State and around the world.  Visit us at SCBIO.org.

  • Sam Patrick posted an article
    Nephron CEO Lou Kennedy honored with national award see more

    Nephron Pharmaceuticals President and CEO Lou Kennedy was honored on Thursday by the National Association of Manufacturers (NAM) with an award for outstanding leadership in manufacturing.  Ms. Kennedy is also the Board Chair of South Carolina's life sciences organization, SCBIO.

    NAM recognized Kennedy at its Manufacturing Institute’s STEP Ahead Women’s Initiative. One of NAM’s largest annual events, the STEP Ahead Award celebrates the achievements of women in manufacturing who inspire the next generation to follow in their footsteps.

    “Nephron is a global leader in pharmaceutical manufacturing, and I am grateful to NAM for recognizing the great work of our team of professionals that delivers safe, effective and affordable medications to patients across the world,” said Kennedy.

    Nephron is a certified woman-owned business, as recognized by the National Women Business Owners Corporation (NWBOC), the first certifier of Women Business Enterprises. The certification gives Nephron enhanced visibility and a competitive edge.

    Nephron’s workforce is forty-four percent women, holding the majority of all advanced degrees at the company. Additionally, women hold key management roles in various departments throughout Nephron, such as Quality Assurance, Chemistry and Microbiology, Regulatory Compliance, Human Resources, Training, R&D Engineering, and Product Development.

     

    About Nephron

    Nephron Pharmaceuticals Corporation develops and manufactures safe, affordable generic inhalation solution and suspension products specializing in Blow-Fill-Seal technology. In addition, the company operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes and IV bags for hospitals across America, in an effort to alleviate their drug shortage needs. In accordance with the DQSA draft guidance, the company follows cGMP, GDP and all quality expectations. The company has been licensed by the Food and Drug Administration. Nephron received a 2017 ISPE/FOYA innovation award for the high level of automation present throughout the facility. For more information, please visit www.nephronpharm.com.

  • Sam Patrick posted an article
    EVENITY Rapidly Reduces Fracture Risk and Builds New Bone With 12 Months of Therapy see more

    Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has approved EVENITY™ (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY is the first and only bone builder with a unique dual effect that both increases bone formation and to a lesser extent reduces bone resorption (or bone loss) to rapidly reduce the risk of fracture. A full course of EVENITY therapy is 12 monthly doses administered by a healthcare provider.2 Since osteoporosis is a chronic disease, continued therapy with an anti-resorptive agent should be considered once EVENITY therapy is completed.

    Click here to read the complete interactive Multichannel News Release... 

  • Sam Patrick posted an article
    DPX Technologies has invested more than $2.5 million and announced an expansion in Columbia, SC see more

    Columbia, SC – DPX Technologies, a manufacturer of laboratory consumable products, has invested more than $2.5 million and announced an expansion in Columbia, SC. The biotechnology company purchased and renovated a 12,000 sq. ft facility on 5 acres in the SCRA Carolina Research Park.

    DPX manufactures patented sample preparation products and specializes in custom workflows for a diverse client base including clinical, forensic, food safety, and pharmaceutical industries. Their products offer sample preparation solutions that are compatible with semi-automated and fully automated liquid handling systems. This enables high sample throughput and high laboratory efficiency.

    Read on for complete details on this story.

  • Sam Patrick posted an article
    SCBIO's expanded Board of Directors includes life sciences leaders from across South Carolina see more

    Organization’s Boards spans state, industry segments to provide unique blend of expertise for advancing South Carolina’s life sciences industry

     

    GREENVILLE, SC – February 8, 2019 – Less than two years after initiating a comprehensive relaunch of the state’s official life sciences organization, SCBIO has expanded its Board of Directors for its 501c6 operational entity and added a second 10-member Board for its 501c3 research and educational arm for 2019.  It does so having authored the state’s first-ever life sciences strategic growth plan, conducted an economic impact study validating the contributions of the $11.4 billion industry, tripled revenues and quadrupled membership – all since Spring 2017.

    And according to SCBIO President and CEO Sam Konduros, the best and most exciting days for the industry and organization are still ahead of it.

    “In a state perhaps best known for building BMWs and Boeing Dreamliners, there is a very strong life sciences story brewing as well, creating opportunities to diversify and accelerate growth of our state’s knowledge economy,” said Konduros recently.  He further cited rapid growth of such national and global brands including Nephron Pharmaceuticals, Arthrex, ZEUS, Abbott, Thorne and AVX as just a few examples of the state’s rapidly rising life sciences industry, which currently spans more than 400 companies in 44 counties and employs over 15,000 well-paid associates.

    Leading the policy- and strategy-making efforts of the 501c6 entity of the non-profit organization, the Board of Directors meets regularly to receive updates on SCBIO business objectives, domestic and global initiatives, and to help hone strategies and offer insight.  Nephron Pharmaceuticals Corporation CEO Lou Kennedy will serve as SCBIO’s 2019 Board Chair; Stephanie Yarbrough, Womble Bond Dickinson, LLP as Vice Chair; Michael Rusnak, Medical University of South Carolina Research Foundation as Treasurer; and Josh Ridley of ZEUS as Secretary. 

    Jeff Stover of Haynsworth Sinkler Boyd, PA will serve as Legal Officer; Heather Simmons Jones of the Greenwood Partnership Alliance as Annual Conference Officer; Bryan Davis of Prisma/Greenville Health System’s Office of Innovations as Healthcare/Innovation Officer; Adam Hoots of DPR Construction as Talent/Workforce Officer; and Sam Konduros, President and CEO of SCBIO. 

    Recently added members of the SCBIO Board of Directors are:

    Mike Briggs – President & CEO, Central SC Alliance

    Caroline Brown – Director of External Affairs, Medical University of South Carolina

    Thornton Kirby – President & CEO, South Carolina Hospital Association

    Adam Klonecke – Senior Site Director, Abbott

    Angie Leidinger – VP of External Affairs, Clemson University

    Tom McKenna – Chief Operating Officer, Thorne

    Robert Ryan – CEO & Founder, Innova Therapeutics

    Dave Shalaby – President, Poly-Med, Inc.

    Will Williams – President & CEO, Economic Development Partnership (Aiken)

    Cynthia Young – Dean, Clemson University College of Science

     

    Returning members of the SCBIO Board for 2019 are:

    Mandy Brawley – South Carolina Department of Commerce

    Matthew Couvillion – Wyche Law Firm

    John J. Darby – Johnson & Johnson Services

    Tressa Gardner – SE Institute of Manufacturing & Technology

    Mike Graney – Charleston Regional Development Alliance

    Chad Hardaway – University of South Carolina Office of Economic Engagement

    Will Harms – Blue Cross Blue Shield of SC

    Erica Jackson – K&L Gates

    Marc Metcalf – Upstate SC Alliance

    Kathy Phlegar – Phlegar & Associates

    Christine Dixon Thiesing – SCRA

    Courtney Warren – Marsh & McLennan Agency

     

    Comprising the smaller Board of SCBIO’s 501c3 research and educational arm are Kathryn Becker of Translational Science Solutions; Michael Bolick of Treis Blockchain; Matthew Couvillion of Wyche Law Firm; Shontavia Johnson of Clemson University; Steve Johnson of SCRA; Chris Przirembel, retired Clemson University executive; Shawn Regan of Rhythmlink; Craig Walker of Hitachi Healthcare Americas; Erica Jackson of K&L Gates; and SCBIO CEO Sam Konduros.

    SCBIO is South Carolina’s investor-driven public/private economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.  The industry has an $11.4 billion annual economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products.  The state-wide nonprofit has offices in Greenville, Columbia, and Charleston, and represents companies in advanced medicines, medical devices, diagnostics, IT, and healthcare outcome industries.

    SCBIO is the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations.  SCBIO members include academic institutions, biotech companies, med-tech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotech and med-tech products that will make a difference across the Palmetto State, and around the world.

  • Sam Patrick posted an article
    Top life sciences leaders from across the state have been named to the SCBIO Executive Committee see more

    Leadership team provides strategic blend of economic development, industry, higher education expertise

     

    GREENVILLE, SC – January 17, 2019 – SCBIO has announced its 2019 Executive Committee following formal confirmation at the life science organization’s December 2018 meeting in Columbia.  Nephron Pharmaceuticals Corporation CEO Lou Kennedy will serve a second term as SCBIO’s 2019 Board Chair.

    Ms. Kennedy joined Nephron Pharmaceuticals in 2001, and assumed the position of President and CEO in 2007. She has held a variety of marketing and operational roles during her career and has helped Nephron Pharmaceuticals grow by more than 300% and increased shipped product to one billion doses each of the last seven years.  Nephron constructed a state of the art manufacturing facility in West Columbia, South Carolina and, with her husband Bill, helped establish the Kennedy Pharmacy Innovation Center in conjunction with the USC School of Pharmacy.  The organization was honored as an inaugural winner of the South Carolina Life Sciences Pinnacle Award for Organizational Contribution to the industry in October, 2018.

    Joining Ms. Kennedy on the SCBIO Executive Committee will be Stephanie Yarbrough, Partner with Womble Bond Dickinson, LLP as Vice Chair; Michael Rusnak, Executive Director of the MUSC Foundation for Research Development as Treasurer; and Josh Ridley, Global Business Development Director of ZEUS as Secretary.  

    Additional members of the Executive Committee are Jeff Stover, Special Counsel with Haynsworth Sinkler Boyd, PA as Legal Officer; Heather Simmons Jones, CEO of the Greenwood Partnership Alliance as Annual Conference Officer; Bryan Davis, Operations Manager with Greenville Health System’s Office of Innovations as Healthcare/Innovation Officer; Adam Hoots, Life Sciences Market Leader for DPR Construction as Talent/Workforce Officer; and Sam Konduros, President and CEO of SCBIO. 

    Recognized for completing their terms as contributing members of the SCBIO Executive Committee were former Vice Chair Craig Walker, executive with Hitachi Healthcare Americas, and former Secretary Kathryn Becker, Principal with Translational Science Solutions LLC.

    SCBIO President and CEO Konduros praised the Executive Committee noting, “With the critically important efforts we are undertaking to advance pharmaceuticals, life sciences R&D, biotech, med-tech, and the health IT industries in South Carolina, we require strong, expert leadership from across the state, fully integrating our business, education and economic development sectors. These diverse leaders who represent the width and breadth of our state and industry will effectively champion our vision of building the business of life sciences in South Carolina for years to come.”

    SCBIO is South Carolina’s investor-driven public/private economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.  The industry already has an $11.4 billion annual economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products.  The state-wide nonprofit has offices in Greenville, Columbia, and Charleston, and represents companies in the advanced medicines, medical devices, equipment, diagnostics, IT, and healthcare outcome industries.

    The Executive Committee and Board of Directors is the policy- and strategy-making body of the organization, and meets regularly to receive updates on SCBIO business and objectives, as well as domestic and global initiatives. The Executive Committee serves roles specific to SCBIO operations, focus areas and strategies.

    SCBIO is the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations.  SCBIO members include academic institutions, biotech companies, med-tech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotech and med-tech products that will make a difference across the Palmetto State, and around the world.

    For additional information on SCBIO, visit www.SCBIO.org

  • Sam Patrick posted an article
    Despite ominous warnings and fearsome weather, Nephron Pharmaceuticals is stepping up again see more

    As Hurricane Florence bears down on the Carolinas, manufacturers are stepping up to help those impacted as best they can. South Carolina-based Nephron Pharmaceuticals, with a facility in West Columbia, SC, is providing assistance to the community in a unique way.

    Natural disasters can cause emergency drug shortages that can further impound the crisis. With that in mind, Nephron’s South Carolina facility is planning to remain open during the hurricane in order to guarantee a continuous supply of medications and other drugs in case of an emergency shortage.

    Read the full story here as reported by Shopfloor, the exceptional blog of our friends and allies at the National Association of Manufacturers (NAM)

  • Sam Patrick posted an article
    Nephron Pharmaceuticals continued support of educational opportunities by announcing scholarships see more

    The South Carolina Governor’s School for the Arts and Humanities received a $13,800 gift from Nephron Pharmaceuticals to support meal plan scholarships for Midlands students attending the school’s residential high school program.

    “Nephron Pharmaceuticals Corporation is so proud to support arts education in our state. I have seen first-hand the impact of an arts education on the mind of a scientist, and it’s a beautiful thing. Look at a trained violinist and a pharmaceutical product developer. Both pursuits require repetition, dedication, critical thinking and the ability to solve a problem from a variety of angles,” said Lou Kennedy, CEO of Nephron Pharmaceuticals. “At Nephron, we’re always looking for critical thinkers and problem solvers, and that is why we are so passionate about supporting the arts as well as the sciences. We are proud to be a sponsor the South Carolina Governor’s School for the Arts and Humanities, and I encourage my fellow CEOs to support arts education across our state. We’re playing the long game here, and we aim to win.”

    “While the Governor’s School for the Arts is a state-funded and tuition-free public high school, there are still meal plan fees that would present a financial barrier for many families if it weren’t for the support of our generous individual and corporate donors,” said Dr. Cedric Adderley, S.C. Governor’s School for the Arts and Humanities president. “Thanks to Nephron Pharmaceuticals, our emerging artists can pursue their dreams without worrying about costs.”

    While tuition is free for all students attending for the full school year, about 30 percent of Governor’s School for the Arts students receive financial assistance from the Governor’s School for the Arts Foundation to pay for the $3,500 meal plan each year. This plan includes three meals per day for seven days per week during the nine-month school year. Nephron’s gift will provide meal plan scholarships to four Midlands students during the 2018-2019 school year.

    Currently, 52 of the Governor’s School for the Arts’ 236 high school students are from the Midlands region, including Calhoun, Fairfield, Kershaw, Lexington, Orangeburg, Richland, Saluda, and Sumter counties. These students were selected based on their talents exhibited through a comprehensive application and audition process.

    To learn more about the S.C. Governor’s School for the Arts & Humanities, follow @SCGSAH on social media and visit http://www.scgsah.org.

  • Sam Patrick posted an article
    Avara Pharmaceutical Services has completed a South Carolina acquisition from GSK see more

    Avara Pharmaceutical Services, a world-class contract development and manufacturing organization (CDMO), announced that the acquisition of the GlaxoSmithKline (GSK) consumer healthcare manufacturing facility in Aiken, South Carolina (USA) is complete.  Read on for full details...

  • Sam Patrick posted an article
    BIO International Convention, the world’s premier life sciences event, returns to Boston June 4-7 see more

    The BIO International Convention, the world’s premier life sciences event, will return to the Boston Convention & Exhibition Center June 4-7, to celebrate 25 years of advocacy and innovation. The 2018 event is expected to attract more than 16,000 attendees and 1,800 exhibitors from 74 countries – including an SCBIO-led delegation of 20+ from South Carolina --all who will be welcomed in a special, keynote address by ABC’s Robin Roberts.  Read on for full details...

  • Sam Patrick posted an article
    Mount Pleasant's FirstString Research completes $15MM Series B financing see more

    FirstString Research, a clinical-stage biopharmaceutical company, announced today that it has completed a $15 Million Series B financing round. Led by Park West Asset Management LLC and Sophos Capital Management L.P., the Series B financing round brings FirstString’s total investor funding to over $27 Million.

    In connection with the Series B financing, Tony Bartsh of Park West and Neal McConnell of Sophos have joined FirstString’s Board of Directors. “FirstString’s team has developed impressive data for Granexin® across a wide range of wound healing indications. We believe the Series B capital will allow FirstString to accelerate the development pipeline in several promising areas. We look forward to the initiation of two important studies in the first half of 2018” said Tony Bartsh.

     “We are thrilled to have Tony and Neal join our Board,” said Dr. Gautam Ghatnekar, President & CEO and Co-Founder of FirstString Research. “They bring with them a wealth of biopharmaceutical experience and expertise.  We believe that the Park West and Sophos investments provide significant credibility and validation to our innovative technology and clinical strategy.  With this new funding, FirstString will be able to continue our extensive pipeline development and to advance our existing late-stage clinical programs toward approval. ”

  • Sam Patrick posted an article
    Zylö Therapeutics is locating new operations in Greenville County, SC. see more

    GREENVILLE, S.C. – Zylö Therapeutics, a developer of state-of-the-art technology for the pharmaceutical industry, is locating new operations in Greenville County. The company is expected to create 30 new jobs.

     

    Zylö Therapeutics has developed an innovative sustained-release drug-delivery system that delivers traditionally hard-to-deliver therapeutic agents through topical administration. With more than 10 years of research and development, the second generation of this technology continues to improve, providing 24-hour sustained release of a variety of agents, including nitric oxide, curcumin, lidocaine and more.

     

    Zylö Therapeutics is headquartered at the NEXT on Main facility at 101 North Main Street in Greenville, S.C. NEXT is a program of the Greenville Chamber of Commerce that currently supports more than 100 knowledge-based companies in Upstate South Carolina.

    Zylö Therapeutics’ operations will soon include a lab facility, where formulation and product development work will be performed. Those interested in joining the Zylö Therapeutics team should visit www.zylotherapeutics.com for more information.

     

    QUOTES

     

    “With the bulk of our scientists and advisors located in the Northeast corridor, we considered a variety of alternative locations, but Greenville represents a wonderful balance of small-town feel, sophistication, high growth and vibrancy. In addition, the city offers a wealth of start-up resources that will assuredly work to our advantage over time.” – Zylö Therapeutics CEO Scott Pancoast

     

    “To see a company like Zylö Therapeutics choose to invest in our state and our people is an important sign to the business community around the world that South Carolina is the place to be. We’ve worked hard to create a pro-business environment and cultivate a highly-trained workforce, and those efforts continue to pay off.” –Gov. Henry McMaster

     

    “The success of South Carolina’s booming life sciences industry continues to impress, and I congratulate Zylö Therapeutics on today’s tremendous announcement. Over the last two decades, we’ve seen a major transformation in South Carolina’s economy, and innovative companies like Zylö Therapeutics are responsible for it.” –Secretary of Commerce Bobby Hitt

     

    “Greenville County encourages growth in the bioscience sector of our economy. We are proud to welcome Zylö Therapeutics to Greenville as part of our vibrant bioscience community that is pioneering state-of-the-art technologies at the forefront of modern medicine. We wish great success for Zylö Therapeutics.” –Greenville County Council Chairman H.G. “Butch” Kirven Jr.

     

    “Greenville has become increasingly attractive to industry leaders in next-generation medical care, as innovative companies like Zylö Therapeutics seek environments that can help connect resources, support emerging technologies and supply a dedicated workforce. The City of Greenville is thrilled to welcome Zylö to our vibrant downtown and we look forward to being a part of their company’s growth.” –City of Greenville Mayor Knox White

     

    “We are excited to welcome Zylö Therapeutics as the newest member of NEXT and the Greenville startup community. This high-impact, knowledge-based company further strengthens the more-than-150 companies within this vibrant, entrepreneurial ecosystem.” –NEXT CEO John Moore


    FIVE FAST FACTS

     

    • Zylö Therapeutics is locating new operations in Greenville County.
    • The start-up is projected to create 30 new jobs.
    • Zylö Therapeutics is a developer of patented, state-of-the-art technology for the pharmaceutical industry.
    • Headquartered in Suite 315 at 101 North Main Street in Greenville, S.C., the company’s operations will include a laboratory facility focused on formulation and product development.
    • Those interested in joining the Zylö Therapeutics team should visit www.zylotherapeutics.com for more information. 

  • Sam Patrick posted an article
    Nephron announces 5% salary increases thanks to tax cuts law see more

    WEST COLUMBIA, S.C. – Nephron Pharmaceuticals Corporation (Nephron) CEO Lou Kennedy today announced five percent increases for all employees with the exception of commissioned employees.  The raises are a direct result of the Tax Cuts and Jobs Act that was signed into law last week by President Donald Trump.

    “We are excited that the Tax Cuts and Jobs Act has given us an opportunity to recognize their hard work and sacrifices with well-deserved raises”, said Lou Kennedy, CEO of Nephron.

    Elected officials – including The Honorable Henry McMaster, Governor of South Carolina, U.S. Senator Lindsey Graham, Congressman Joe Wilson, state legislators and local elected officials – joined Kennedy and Nephron employees for today’s announcement celebration at the company’s West Columbia headquarters. Both of South Carolina’s U.S. Senators and six of the state’s seven members of the U.S. House of Representatives voted in favor of the Tax Cuts and Jobs Act.

    "I am grateful that the tax cuts House Republicans worked so hard to pass have had an immediate impact in the district,” said Congressman Joe Wilson. “I congratulate Lou and Bill Kennedy, as well as Nephron's entire team, on today’s announcement, and I wish them continued success.”

    Nephron is a manufacturer of respiratory and compounded 503B outsourcing medications that employs 640 people in West Columbia. The company, which launched 34 new products in 2017, recently announced a $12.5 million expansion and expects to add 125 additional employees by June 2018.

    Fifty percent of Nephron employees attended South Carolina universities or technical colleges. Nephron founder Bill Kennedy and CEO Lou Kennedy are University of South Carolina graduates and South Carolinians. The company is part of the life sciences industry in the State.  This industry has a total $11.4 billion annual impact on the State economy.

    For more information about Nephron, visit http://www.nephronpharm.com.

  • Sam Patrick posted an article
    Top speakers and brands are committing to attend SCBIO 2017 in Charleston this October; have you sig see more

    BIO global CEO Jim Greenwood will join South Carolina Governor Henry McMaster as featured luncheon speakers on the first full day of SCBIO 2017 – the annual conference bringing top leaders and executives from organizations across the life sciences industry to Charleston, South Carolina October 24–26.

    Mr. Greenwood will be addressing the gathering with a keynote presentation entitled “Global Trends for the Life Sciences Industry – and Implications for South Carolina” at lunch on October 25.  South Carolina Governor Henry McMaster will follow with a presentation entitled “Life Sciences Powered by Public/Private Partnership – A Strategic View from the Statehouse.”

    Dozens of top industry chief executives, leaders in government and higher education, biotechnology and pharma executives, and industry supporters from across America have already committed to attend SCBIO 2017 at Charleston’s Gaillard Auditorium, organizers confirmed today.  Among the committed speakers and panelists are Nephron Pharmaceuticals CEO Lou Kennedy, MUSC President David Cole, Clemson University President Jim Clements, USC President Harris Pastides, Medpoint CEO Chuck Crumpton, Belimed CEO Joseph McDonald, AVX Health Division executive Robert Fairey and numerous others.

    Themed “Building the Business of Life SCiences in SC”, the 2+ day conference draws attendees from across America for networking, innovation updates, opportunity discovery, partnership making and strategic discussion.  Committed attendees include officials across a broad spectrum of life sciences industries including medical devices, bio manufacturing, drug discovery, pharmaceuticals, diagnostics and testing, digital health and health IT, bio ag  and more.  While space is limited and advance registration is required, interested attendees can still register at http://scbio2017.eventbrite.com.

    SCBIO is South Carolina’s investor-driven economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.  The industry has an $11.4 billion economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotechnology products. 

    SCBIO 2017 kicks off Tuesday evening with a Welcome Reception for conference registrants, speakers and sponsors on the rooftop terrace of the Grand Bohemian Hotel.  Wednesday will feature a full day of sessions beginning at breakfast with a greeting by Charleston Mayor John Tecklenburg and continuing through an evening reception.  The conference will wrap up Thursday at lunchtime. 

    “The life sciences industry has become a major driver of South Carolina’s economy,” noted South Carolina Secretary of Commerce Bobby Hitt recently. “Already accounting for thousands of highly-skilled jobs in the Palmetto State, we know that this sector has tremendous growth potential, and we’re excited to be partnering with SCBIO to help life sciences continue to advance in South Carolina.”  SC Commerce is a Founding Partner of SCBIO and of the Conference.

    Among the leading biotech industry brands participating in the conference are Nephron Pharmaceutical, BIO, Johnson & Johnson, AVX, PhRMA, Medpoint, AdvaMed, Poly-Med, VWR, Ritedose Corporation, Rhythmlink, Softbox, NCGS and SEMDA.  All of South Carolina’s research universities – MUSC, Clemson and the University of South Carolina – are attending, as is Greenville Health System and economic development entities including SCRA, the Upstate SC Alliance, the Charleston Regional Development Alliance and SiMT.

    As the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations – SCBIO members include hundreds of academic institutions, biotech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products that transform how we heal, fuel and feed the world.

    For additional information on SCBIO, visit www.SCBIO.org.  To register for SCBIO 2017, visit http://scbio2017.eventbrite.com

  • Sam Patrick posted an article
    Hundreds of industry executives to convene Oct. 24-26 in Charleston, SC see more

    GREENVILLE, SC – Hundreds of industry executives, leaders in government and higher education, biotechnology and pharma executives, and industry supporters from across America will convene in Charleston, South Carolina for SCBIO 2017 – SCBIO’s Annual Conference -- October 24-26, 2017 at Charleston’s Gaillard Auditorium, organizers announced today.  Among the committed speakers and panelists are South Carolina Governor Henry McMaster, BIO Chief Executive Jim Greenwood, Nephron Pharmaceuticals CEO Lou Kennedy, MUSC President David Cole, and others.

    Early bird registration is now open for the conference, themed “Building the Business of Life SCiences in SC”, which draws attendees for intensive networking, innovation updates, opportunity discovery, partnership making and strategic discussion.  Registrants expected include top officials across a broad spectrum of life sciences industries including medical devices, bio manufacturing, drug discovery, pharmaceuticals, diagnostics and testing, digital health and health IT, bio ag  and more.  Interested attendees and sponsors can register at SCBIO 2017 Registration on Eventbrite for full details.  Advance registration is required, and space is limited.

    SCBIO is South Carolina’s investor-driven economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.  SCBIO members are involved in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotechnology products.  The industry has an $11.4 billion economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the state’s burgeoning industry.

    SCBIO 2017 kicks off Tuesday evening with a Welcome Reception for conference registrants, speakers and sponsors on the rooftop terrace of the Grand Bohemian Hotel.  Wednesday will feature a full day of sessions beginning with a Welcome Breakfast, greeting by Charleston Mayor John Tecklenburg and an Industry CEO Panel.  A report on South Carolina’s exploding Life Sciences Industry featuring SCBIO CEO Sam Konduros and USC Darla Moore School of Business leader Dr. Joey Von Nessen will follow, as will a presentation by SC Deputy Secretary of Commerce Jennifer Fletcher.  SC Commerce is a Founding Partner of SCBIO and of the Conference.

    “The life sciences industry has become a major driver of South Carolina’s economy,” noted South Carolina Secretary of Commerce Bobby Hitt recently. “Already accounting for thousands of highly-skilled jobs in the Palmetto State, we know that this sector has tremendous growth potential, and we’re excited to be partnering with SCBIO to help life sciences continue to advance in South Carolina.”

    Wednesday’s program continues with a second CEO panel of leaders from South Carolina’s biotech industry delivering insight on organizational challenges and opportunities – including presenting sponsor Nephron Pharmaceutical CEO, Lou Kennedy, whose company has invested close to $400 million and recently relocated their global headquarters to the Palmetto State.

    ”South Carolina is a great home for the life sciences cluster, and Nephron Pharmaceuticals is happy to be part of it – and we thank SCBIO for its leadership,” stated Kennedy. The industry CEO panel will be followed by a luncheon featuring a keynote by Jim Greenwood, CEO of BIO.  Comments from South Carolina Governor Henry McMaster will follow Mr. Greenwood’s presentation.

    Highlights of Wednesday afternoon will include presentations on the transformational role of the state’s research institutions in our knowledge economy featuring MUSC David Cole and leaders from the state’s other research universities, followed by an interactive panel discussion with nationally respected venture capitalists on attracting additional capital to the state.  A reception for all registrants will follow.

    Thursday will cap SCBIO 2017 with a breakfast event designed to engage conference attendees directly in the strategic discussion, catalyzed by a presentation on “Building SC’s Life Sciences Industry” delivered by CEOs of scaling-up life sciences companies.  An interactive SWOT session on the needs of the industry in South Carolina will follow, and Thursday will culminate with self-selected interactive and facilitated sessions at which each attendee can interface with industry leaders, panelists, presenters and stakeholders of their choosing.

    As the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations – SCBIO members include scores of academic institutions, biotech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related organizations whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products that transform how we heal, fuel and feed the world.

    Committed sponsors of SCBIO 2017 include the South Carolina Department of Commerce; Nephron Pharmaceuticals; SCRA; Charleston Harbor Entrepreneur Center; KDS Commercial Real Estate; MUSC; the Charleston Regional Development Alliance; AVX; SiMT; Clemson University; University of South Carolina; the Upstate Alliance; VWR; SEMDA and many more.

    For additional information on SCBIO, visit www.SCBIO.org.  To register for SCBIO 2017, visit Event Brite and search “SCBIO 2017 annual conference”.